Regulators, industry tout new approach for benefits-risk assessments
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesGlobalPharmaceuticalsProduct LifecycleRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesGlobalPharmaceuticalsProduct Lifecycle